Published in Br Med J on November 21, 1970
Controlled trial of active immunotherapy in management of stage IIB malignant melanoma. Br Med J (1977) 1.08
Attempts at stimulation of immune response in acute lymphod leukaemia. Proc R Soc Med (1972) 0.79
Transience of immune responses to tumour antigens in man. Br Med J (1971) 0.76
A microassay for cell-mediated immunity. Transplantation (1970) 4.29
Demonstration of antibodies against human malignant melanoma by immunofluorescence. Surgery (1968) 3.56
Tumour-specific antibodies in human malignant melanoma and their relationship to the extent of the disease. Br Med J (1969) 3.37
Possible immunological factors in human malignant melanoma in Uganda. Lancet (1967) 3.16
Autoimmunization with irradiated tumour cells in human malignant melanoma. Br Med J (1970) 2.91
Stimulation of lymphocytes by autologous leukaemic cells in acute leukaemia. Nature (1969) 2.75
Spontaneous regression of primary malignant melanomas with regional metastases. Cancer (1965) 2.15
Suspension culture of a pigment-producing cell line derived from a human malignant melanoma. J Natl Cancer Inst (1968) 1.84
Detection by immunofluorescence of antibodies specific for human malignant melanoma cells. Cancer (1969) 1.60
The role of immunoblasts in host resistance and immunotherapy of primary sarcomata. Adv Cancer Res (1970) 1.32
Spontaneous regression of human melanoma: clinical and experimental studies. Cancer (1960) 1.30
The incidence and distribution of pigmented naevi in Ugandan Africans. Br J Dermatol (1968) 1.17
Aspects of behavior and natural history of malignant melanoma in Uganda. Cancer (1968) 1.15
Leukemia-associated antigens in the mixed leukocyte culture test. Science (1969) 1.12
Prospects for immunotherapy of cancer: experience in experimental systems. Br Med J (1970) 1.11
SPONTANEOUS REGRESSION OF MALIGNANT MELANOMA. Am Surg (1964) 1.06
Formal discussion: long-term survival in Burkitt's tumor and in acute leukemia. Cancer Res (1967) 0.82
Tumour-specific antibodies in human malignant melanoma and their relationship to the extent of the disease. Br Med J (1969) 3.37
Management of adult acute myelogenous leukaemia. Br Med J (1973) 3.33
Autoimmunization with irradiated tumour cells in human malignant melanoma. Br Med J (1970) 2.91
Immunity to malignant disease in man. Br Med J (1969) 2.88
Immunization with irradiated tumour cells and specific lymphocyte cytotoxicity in malignant melanoma. Br Med J (1971) 2.82
Immunotherapy for acute myelogenous leukaemia. Br J Cancer (1973) 2.67
Combination chemotherapy using L-asparaginase, daunorubicin, and cytosine arabinoside in adults with acute myelogenous leukaemia. Br Med J (1970) 2.51
Recognition of leukaemia cells as foreign before and after autoimmunization. Br Med J (1971) 2.50
Lymphoid cellular responses in the blood after immunization in man. J Exp Med (1969) 2.25
Combination chemotherapy in generalized Hodgkin's disease. Br Med J (1970) 1.67
Clinical validation of an autoantibody test for lung cancer. Ann Oncol (2010) 1.55
L-asparaginase in treatment of acute leukaemia and lymphosarcoma. Br Med J (1970) 1.39
Significance of the changes in the circulating lymphoid cells in Hodgkin's disease. Br Med J (1969) 1.35
Combination chemotherapy in advanced and recurrent Hodgkin's disease. Natl Cancer Inst Monogr (1973) 1.33
Acute leukemia in adults. Semin Hematol (1974) 1.28
Lymphoid cells in Hodgkin's disease. Nature (1967) 1.23
Cellular resistance to tumours. Br Med Bull (1967) 1.22
Safe method of collecting leukaemia cells from patients with acute leukaemia for use as immunotherapy. Br Med J (1974) 1.15
Hypoplastic acute myelogenous leukaemia. Br J Haematol (1975) 0.95
Treatment of polycythaemia vera. Br Med J (1967) 0.86
Changes in the lymphoid cell population of peripheral blood in man during immune responses. Br J Haematol (1968) 0.84
Desoxyribonucleic acid synthesis in the lymphocytes of patients with malignant disease. Eur J Cancer (1967) 0.83
Human resistance to tumours. Proc R Soc Med (1967) 0.78
Circulating lymphoid cells in Hodgkin's disease. Natl Cancer Inst Monogr (1973) 0.78
Leukemias and lymphomas. Semin Hematol (1974) 0.77
Detection of tumor specific immune reactions in human melanoma. Ann N Y Acad Sci (1971) 0.77
Immunotherapy for acute myelogenous leukemia. Bibl Haematol (1975) 0.76
Evidence for antigenicity in human tumours with reference both to melanoma and acute leukemia. Proc R Soc Med (1971) 0.75
Chemotherapy of Hodgkin's Disease with Cyclophosphamide, Vinblastine, and Procarbazine. Br Med J (1966) 0.75
Hodgkin's disease. Nurs Times (1967) 0.75
Inhibitation by L-asparaginase from E. coli of human malignant melanoma cells growing in vitro. Recent Results Cancer Res (1970) 0.75
Autoantibodies in malignant disease. Br J Haematol (1972) 0.75
The treatment of Hodgkin's disease. Trans Med Soc Lond (1972) 0.75
Blood and neoplastic diseases. Treatment of the lymphomas. Br Med J (1974) 0.75
Immunity in malignant disease. Trans Med Soc Lond (1968) 0.75
The use of different drugs and combinations in the treatment of Hodgkin's disease. Ser Haematol (1973) 0.75
Letter: Repeated acupunctures and serum hepatitis. Br Med J (1974) 0.75
The place of combination chemotherapy in the treatment of malignant disease. Br J Radiol (1973) 0.75
The periodic acid-Schiff reaction of lymphocytes in human malignant disease. Br J Haematol (1969) 0.75
Blast crisis of chronic myeloid leukaemia: the effect of intensive chemotherapy. Scand J Haematol (1976) 0.75
The treatment of acute myeloblastic leukaemia. Br J Haematol (1971) 0.75
Combination chemotherapy in malignant diseases. J R Coll Physicians Lond (1971) 0.75
Changes in the lymphoid cells of the peripheral blood in Hodgkin's disease. Br J Haematol (1968) 0.75
Smooth muscle antibody in malignant disease. Nouv Rev Fr Hematol (1973) 0.75
Immunity to malignant disease in man. Minerva Pediatr (1971) 0.75
Immunity to malignant disease in man. Sci Basis Med Annu Rev (1971) 0.75
Immunotherapy in the management of myelogenous leukemia. Arch Intern Med (1976) 0.75